Literature DB >> 2353417

Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone.

J E Burkhardt1, M A Hill, W W Carlton, J W Kesterson.   

Abstract

The histologic and histochemical features of quinolone-induced arthropathy were studied using 14 skeletally immature Beagle dogs (3 to 4 months old) dosed orally with difloxacin at 300 mg/kg body weight once daily for 1, 2, 5, or 7 days. A placebo was given to eight other age-matched Beagle dogs that served as controls. A scoring technique that included lesion size and histologic features was used to determine the progression of lesions. Articular-epiphyseal cartilage complexes on the femoral and humeral heads and tibial tarsal bone were identified as predilection sites. Within predilection sites on femoral and humeral heads, lesions developed in specific areas. Lesions appeared within 2 days of the onset of treatment, and lesion scores increased with time. Grossly, the lesions were raised, fluid-filled vesicles on the articular surface. Histologic changes included vesicle formation with loss of proteoglycan, clumping of unmasked collagen, and degeneration and necrosis of chondrocytes. In lesions with higher scores, chondrocytes were often in clusters or they were undergoing metaplasia toward spindle-shaped cells. Although dissolution of matrix and necrosis of chondrocytes were typical of all lesions, smaller lesions had histologically normal chondrocytes adjacent to small vesicles. In sections stained with toluidine blue, proteoglycan was aggregated with collagen fibrils or was absent from the matrix adjacent to vesicles. Unique features, such as biomechanical forces, may predispose specific areas of articular cartilage to develop lesions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2353417     DOI: 10.1177/030098589002700303

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  24 in total

1.  Serum concentrations and pharmacokinetics of enrofloxacin after intravenous and intragastric administration to mares.

Authors:  G R Haines; M P Brown; R R Gronwall; K A Merritt
Journal:  Can J Vet Res       Date:  2000-07       Impact factor: 1.310

2.  A reappraisal of quinolone tolerability. The experience of their musculoskeletal adverse effects.

Authors:  G Hayem; C Carbon
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

3.  Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration.

Authors:  Aric R Adams; Gregory R Haines; Murray P Brown; Ronald Gronwall; Kelly Merritt
Journal:  Can J Vet Res       Date:  2005-07       Impact factor: 1.310

4.  Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.

Authors:  D B Bethell; N P Day; N M Dung; C McMullin; H T Loan; D T Tam; L T Minh; N T Linh; N Q Dung; H Vinh; A P MacGowan; L O White; N J White
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice.

Authors:  M A Simonin; P Gegout-Pottie; A Minn; P Gillet; P Netter; B Terlain
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 6.  Safety profile of the fluoroquinolones: focus on levofloxacin.

Authors:  Hans H Liu
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

Review 7.  Safety and tolerability of fluoroquinolones.

Authors:  S R Norrby; P S Lietman
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 8.  Use of the quinolones in paediatrics.

Authors:  U B Schaad
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Chondrotoxicity of quinolones in vivo and in vitro.

Authors:  H Hildebrand; G Kempka; G Schlüter; M Schmidt
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

10.  Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.

Authors:  S Payen; R Serreau; A Munck; Y Aujard; Y Aigrain; F Bressolle; E Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.